Abstract: A gum-like device is designed for the controlled and continued delivery of rifaximin, without producing the usually intense red coloration, for the resolution of the infections and the reduction of the inflammation in the oral cavity and in the laryngo-pharyngeal one. The device also protects either the gum or the dental apparatus from acute infections, from the infiltration and the stagnation of the food, and fights chronic infections such as in the periodontal pockets. Moreover, the device can be used to protect the gum from the traumatizing collision that the food exercises during the mastication.

Abstract: The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof.

Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.

Abstract: The invention relates to an oral, multiparticle pharmaceutical dosage form containing pellets, the size of which ranges from 50 to 2500 ?m and which essentially consist of: a) an inner matrix layer containing an active substance which is a peptide or a protein, including the derivatives or conjugates thereof, and which is embedded in a matrix consisting of a polymer with mucoadhesive effect, and b) an outer film coating essentially consisting of an anionic polymer or copolymer, which can be optionally formulated with pharmaceutically conventional adjuvants, more particularly softening agents.

Abstract: Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3.

Abstract: Described herein are nanoemulsions comprising (1) at least one fluoro ether and (2) a block copolymer comprising a hydrophilic block and hydrophobic block, wherein the nanoemulsion comprises a therapeutic agent in the nanoemulsion. The nanoemulsions are stable and are excellent drug delivery devices for ultrasound-mediated, image guided drug delivery. Also described herein are methods for using the nanoemulsions to treat tumors and cancers as well as using them as imaging agents.

Abstract: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.

Abstract: The invention comprises the use of one or more charged surfactants in preparations having an antiperspirant effect for reducing staining in or on clothing and improving improvement the ability of stains to be washed out of the clothing.

Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.

Abstract: The present invention provides compositions comprising an interpolymer of chitosan and polyethylene glycol, wherein the interpolymer is a liquid below 25° C. and a gel above 35° C. The present invention also provides methods for using the compositions to deliver drugs to a living body over time.

Abstract: Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against Chlamydia.

Abstract: This invention relates to chemical compositions comprising two thickening components, which are sclerotium gum and a copolymer selected from the group consisting of methyl vinyl ether/maleic anhydride copolymer and acryloyldimethyltaurate vinylpyrrolidone copolymer, in particular the ammonium salt of the latter; which components provide good thickening properties in the presence of electrolytes, in particular in the presence of ethanolamine or vitamin salts. Further there are provided cosmetic formulations comprising these thickening components.

Abstract: In a process for producing organic substrate particles bonded to switchable ferromagnetic nanoparticles with a mean particle diameter in the range from 10 to 1000 nm, the ferromagnetic nanoparticles used are those nanoparticles which are nonferromagnetic at first, but become ferromagnetic when the temperature is lowered, these at first nonferromagnetic nanoparticles in dispersed form are bonded to the organic substance particles, and then the nanoparticles bonded to the substrate particles are made ferromagnetic as a result of the temperature being lowered.

Abstract: The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.

Abstract: The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in a weight ratio of about 1:0˜10. The capsule wall material is composed of a capsule wall matrix, a plasticizer and water in a weight ratio of 1:0.2˜0.4:0.8˜1.3. The soft capsule of butylphthalide described in the present invention can mask the strong and special flavor of butylphthalide, and overcome the difficulties associated with formulating oily active ingredient into other oral formulation. The disintegration time of the soft capsule satisfies the requirement of Pharmacopoeia of P.R. China.

Abstract: A new treatment regime is presenter using a low concentration formulation at a low dosage of hydrophobic photosensitizers (PS) that shows improved pharmacokinetics and an effective method for photodynamic therapy (“PDT”). The new formulation has better pharmacological effect compared to standard photosensitizer formulation with standard dosage. It was found that PDT treatments using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. It was found that the inventive formulation; (1) reduces the time for a therapeutically effective level of photosensitizer to accumulate in diseased tissue; and, (2) reduces the time for achieving a sufficient ratio of photosensitizer in diseased tissue vs. healthy tissue. As a result, the formulation of the invention reduces the time interval between PS application/administration and irradiation (the drug-light interval or “DLI”) and can provide for a “same day” PDT treatment option.

Abstract: The invention provides porous particles, a process for producing the porous particles, and cosmetics comprising the porous particles. The porous particles of the invention have an average particle diameter of 75 ?m or less, based on polyethylene resin having a crystallization degree of 70% or more. The porous particles further comprise an active ingredient. The process for producing the porous particles, comprises mixing polyethylene resin having a crystallization degree of 70% or more, and a low-molecular weight compound having a melting point lower than the softening temperature (or melting point) of the polyethylene resin, with each other at a temperature not lower than the softening temperature (or melting point) of the polyethylene resin, then spraying the mixture into a gaseous phase or a solvent at a temperature at which the viscosity of the mixture becomes 600 mPa·s or less, and removing the low-molecular weight compound from the resulting particles.

Abstract: This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture.

Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

Abstract: A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. One disclosed method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.